<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> <z:mp ids='MP_0005039'>hypoxia</z:mp> and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> metabolism are linked through the activation of metabolic genes following <z:mp ids='MP_0005039'>hypoxia</z:mp>-inducible factor 1 (HIF-1) activation </plain></SENT>
<SENT sid="1" pm="."><plain>This raises the question of whether this relationship can be exploited to improve 2-deoxy-2-[(18)F]fluoro-<z:chebi fb="0" ids="4167">D-glucose</z:chebi> <z:chebi fb="4" ids="30225">positron</z:chebi> emission tomography ([(18)F]FDG-PET) </plain></SENT>
<SENT sid="2" pm="."><plain>To do this, [(18)F]FDG uptake was investigated after chemical induction of <z:mp ids='MP_0005039'>hypoxia</z:mp> and chemical activation of HIF-1 in an in vitro and an in vivo model of a human colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>[(18)F]FDG uptake, HIF-1α protein levels, and messenger <z:chebi fb="3" ids="33697">ribonucleic acid</z:chebi> expression of <z:chebi fb="105" ids="17234">glucose</z:chebi> transporter 1 (GLUT1), hexokinase 2, HIF-1α, and carbonic anhydrase IX (CA IX) were determined in HT29 cells after treatment with 200 μM CoCl(2) and 500 μM dimethyloxalylglycine (DMOG) </plain></SENT>
<SENT sid="4" pm="."><plain>In an HT29 xenograft, the distribution of endogenous and exogenous markers of <z:mp ids='MP_0005039'>hypoxia</z:mp> was investigated using immunohistochemistry, and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> [(18)F]FDG uptake was determined after treatment with a single dose of 5 mg/kg hydralazine and 8 mg DMOG </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment of HT29 cells with CoCl(2) and DMOG induced functional HIF-1 and resulted in increased [(18)F]FDG uptake </plain></SENT>
<SENT sid="6" pm="."><plain>In an HT29 xenograft, a similar spatial distribution of pimonidazole, CA IX, and GLUT1 was found, and treatment with DMOG resulted in significant increases in maximum and mean standardized uptake values using [(18)F]FDG-PET </plain></SENT>
<SENT sid="7" pm="."><plain>Chemical activation of HIF-1 can increase in vitro and in vivo [(18)F]FDG uptake </plain></SENT>
<SENT sid="8" pm="."><plain>Imaging after pharmacologic HIF-1 activation might increase <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> [(18)F]FDG uptake when using [(18)F]FDG-PET </plain></SENT>
</text></document>